IDDF2020-ABS-0169 Development of virological breakthrough in treatment naïve hepatitis B patient receiving tenofovir: a case report

Ignatius Bima Prasetya, Nata Pratama Hardjo Lugito, Andree Kurniawan
2020 Abstracts   unpublished
majority of patients were symptomatic (92%): jaundice (68%), abdominal pain (35%), fever (17%) and rash (15%). Hepatic encephalopathy was present in 32%. Laboratory patterns of DILI were: hepatocellular (R value>5) 54%, cholestatic (R<2) 28% and mixed (R=2-5) 19%. Hy's law was met in 48% while 26% had ALF (encephalopathy + INR > 1.5). The median admission MELD score was 21. 35% of patients received corticosteroids, and 15% received ursodeoxycholic acid. ICU admission and haemodialysis occurred
more » ... odialysis occurred in 35% and 11%, respectively. During the study period, there were 12 deaths and 12 LT. The 90-day LT-free survival was 71%. Univariate predictors for LT or mortality at 90 days were: jaundice (HR 9.77, P=0.027), encephalopathy (HR 2.70, P=0.036), hepatocellular pattern (HR 2.85, P=0.047), fulfilling Hy's Law (HR 2.71, P=0.046) and MELD (HR 1.14, P<0.001). On multivariable analysis, only MELD remained predictive of worse 90-day LT-free survival (HR 1.14 per point increase, P<0.001). Conclusions At this LT centre, 30% of patients hospitalised for non-paracetamol DILI experienced death or LT at 90 days. The proportion of cases due to non-prescription drugs increased over time. MELD score predicted for adverse outcomes. Abstracts Gut 2020;69(Suppl 2):A1-A95 A85 on December 20, 2020 by guest. Protected by copyright.
doi:10.1136/gutjnl-2020-iddf.159 fatcat:etidkjzdsbaq7jaz6vrjrzwiga